BridgeMD
HEMODIALYSIS AND ANTIBIOTIC PROPHYLAXIS
EU CTIS ID: 2024-515001-26-00
What this study is testing
In a randomised placebo-controlled trial to evaluate the effect of prophylactic antibiotic treatment with amoxicillin/clavulanic acid (or clindamycin if beta-lactam intolerant), administered in relation to the HD procedure on: BSI and severe blood culture negative infection, during the first 6 months after initiation of hemodialysis with CVC as vascular access.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- End Stage Kidney Disease (ESKD) patients who receive an uncuffed or cuffed CVC for expected chronic HD, regardless of previous ESKD treatment modality (PD or KTX) and hemodialysis access (AV-fistula or AV-graft))
You likely can't join if
- Unable to give informed consent
- Known intolerance to beta-lactam antibiotics and clindamycin
- Active infection treated with antibiotics
- Pregnancy. In women of childbearing age, an approved birth control must be ensured
- Patients may be rescreened later i.e. within a time period of one month from start of HD, if exclusion criteria are reversible
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.